From: The impact of prothrombin complex concentrates when treating DOAC-associated bleeding: a review
 | RE-LY [5] | ROCKET-AF [6] | ARISTOTLE [136] | ENGAGE-AF TIMI [4] | ||||||
---|---|---|---|---|---|---|---|---|---|---|
Dabigatran 150 mg (n = 6076) | Dabigatran 110 mg (n = 6015) | Warfarin (n = 6022) | Rivaroxaban (n = 7111) | Warfarin (n = 7125) | Apixaban (n = 9088) | Warfarin (n = 9052) | Edoxaban 60 mg (n = 7012) | Edoxaban 30 mg (n = 7002) | Warfarin (n = 7012) | |
Major bleeding rate (%) per year | 3.11 | 2.71 | 3.36 | 3.6 | 3.4 | 2.13 | 3.09 | 2.75 | 1.61 | 3.43 |
Hazard ratio vs warfarin | 0.93 (0.81–1.07); p = 0.31 | 0.80 (0.69–0.93); p = 0.003 | / | 1.04 (0.90–1.20); p = 0.58 | / | 0.69 (0.60–0.80); p < 0.001 | / | 0.80 (0.71–0.91); p < 0.001 | 0.47 (0.41–0.55); p < 0.001 | / |